Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Sareum Holdings

    MCap

    GBP35m

    Last close

    GBP0.34

    ▲ 10.25 (44.09%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    VolitionRx

    MCap

    USD70m

    Last close

    USD0.85

    ▲ 0.25 (41.67%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

e-therapeutics (LSE: ETX)

Last close As at 23/04/2024

10.03

▲ 0.08 (0.80%)

Market capitalisation

59m

Edison Investment Research is terminating coverage on e-therapeutics (ETX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Upcoming Events

14th May 2024, 8am BST

Edison Growth Conference – May 2024

Latest Insights

Healthcare | edison tv

e-therapeutics showcase

Healthcare | Update

e-therapeutics — More to come in RNAi therapy discovery

Healthcare | Initiation

e-therapeutics — Enhancing siRNA drug discovery with LLMs
e-therapeutics
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (20.0) (39.3) (29.5)
Relative (21.3) (42.4) (29.6)
52 week high/low 23.1p/8.1p

Financials

Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Jan Revenue (£m) EBITDA (£m) PBT (£m) EPS (fd) (p) P/E (x) P/CF (x)
2022A 0.5 (9.4) (9.5) (1.65) N/A N/A
2023A 0.5 (9.8) (9.8) (1.54) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Research